Healthcare Wrap: Lumos Surges, Tissue Repair Sinks as US Expansion Drives Week 30

Lumos Diagnostics (ASX:LDX) led the week with a 30.95% gain after expanding its FebriDx push across US urgent care networks. Investors liked the simple part of the story: more clinic sites can mean more tests sold. Tissue Repair (ASX:TRP) went the other way, sliding 29.09% after it asked to delist from the ASX and offered a buy-back. That move worried investors because delisted shares are usually much harder to trade. ECS Botanics (ASX:ECS) rose 20.00% as it posted a fourth straight quarter of positive operating cash flow, which means the business brought in more cash than it spent from day-to-day operations.

US sales stories drew strong buying

Several of the best performers had a clear US sales angle. Imricor Medical Systems (ASX:IMR) climbed 17.43% after submitting the last major FDA device filing needed for its MRI-guided heart procedure platform. Artrya (ASX:AYA) added 5.22% when its Salix software went live at a second US customer and started earning subscription and scan fees. LTR Pharma (ASX:LTP), down 3.92%, still locked in a US manufacturing deal for ROXUS. PainChek (ASX:PCK) was flat for the week, but the company gave investors two reasons to watch it: a new CEO with deep US medtech experience and a $1.123 million R&D refund to support product work and US validation.

Cancer imaging and radiopharma kept moving

Optiscan Imaging (ASX:OIL) gained 3.23% across a busy week. It started live imaging during head and neck surgery earlier than planned, then launched a Mayo Clinic breast cancer study aimed at future FDA filings. Investors care because these studies can help prove the devices work in real hospitals, not just in a lab. Telix Pharmaceuticals (ASX:TLX) fell 1.68% even after reporting Q2 revenue of US$247 million, up 21%, and securing FDA alignment for the next part of a late prostate cancer trial. Radiopharm Theranostics (ASX:RAD) dropped 5.00%. Its trial news was strong, with RAD101 showing high agreement with MRI scans, but the stock later went into suspension before a capital raising. In plain English, investors liked the science but paused for details on how much new money would be raised and at what price.

Cash mattered almost as much as trial news

Recce Pharmaceuticals (ASX:RCE) raised $4 million and moved an Australian diabetic foot infection study into a pivotal Phase 3 trial, which is a late-stage study used to support approval. Paradigm Biopharmaceuticals (ASX:PAR) received $5.75 million in tax refunds to help fund its osteoarthritis program. Cambium Bio (ASX:CMB) raised just over $1 million at a 17.1% premium, meaning the new shares were sold above the last traded price, which usually signals backing from a supportive investor. IDT Australia (ASX:IDT) rose 6.25% after lifting its revenue forecast and sharply cutting its expected EBITDA loss. EBITDA is a rough measure of operating profit before some major costs.

Good news did not always lift share prices

PolyNovo (ASX:PNV) fell 12.76% despite posting 16.1% revenue growth and a big jump in operating cash flow. OncoSil Medical (ASX:OSL) lost 16.90% after winning Saudi FDA approval for its pancreatic cancer device. Early trading support faded fast, which suggests buyers did not stick around after the first reaction. EBR Systems (ASX:EBR) dropped 15.49% even as it rolled out a newly cleared implant accessory in the US. Genetic Signatures (ASX:GSS) shed 11.76% after outlining a strategic reset and cost cuts. Investors may have focused on the need to reset the business rather than the savings promised for later.

Neuro, rare disease and diagnostics added depth

PYC Therapeutics (ASX:PYC) rose 3.11% on two fronts: better durability data in its optic atrophy program and a dose increase for its kidney disease trial. Entropy Neurodynamics (ASX:ENP) added 2.78% after reporting a 50% remission rate in an early binge eating disorder trial and securing a South African patent for fibromyalgia treatment. Actinogen Medical (ASX:ACW) gained 2.38% as Xanamem showed antidepressant effects in a hard-to-treat depression group. In diagnostics, Proteomics International (ASX:PIQ) still fell 11.43% despite landing a national Healius distribution deal, while Atomo Diagnostics (ASX:AT1) rose 6.25% after reporting 40% revenue growth.